Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis

  • Hoepner R
  • Faissner S
  • Salmen A
  • et al.
N/ACitations
Citations of this article
71Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Natalizumab (Nat) is a humanized monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Nat inhibits lymphocyte migration via the blood brain barrier (BBB) by blockage of an integrin adhesion molecule, very late antigen 4. During the phase III clinical trials, it was shown that Nat reduces disease activity and prevents disability progression. In addition, several smaller studies indicate a positive influence of Nat on cognition, depression, fatigue, and quality of life (Qol). Therapeutic efficacy has to be weighed against the risk of developing potentially fatal progressive multifocal leukoencephalopathy (PML), an opportunistic infection by JC-virus (JCV) with an incidence of 3.4/1000 (95% CI 3.08–3.74) in Nat treated MS patients. In this review article, we will review data on the presumed mechanism of Nat action, clinical and paraclinical efficacy parameters, and adverse drug reactions with a special focus on PML.

Cite

CITATION STYLE

APA

Hoepner, R., Faissner, S., Salmen, A., Gold, R., & Chan, A. (2014). Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis. Journal of Central Nervous System Disease, 6, JCNSD.S14049. https://doi.org/10.4137/jcnsd.s14049

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free